Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-22
    E.g., 2018-09-22

Articles

9064 items
8:53 AM, Aug 23, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting IRE1 or its RNase activity could help treat triple-negative breast cancer (TNBC). In a panel of human breast cancer cell lines, levels of IRE1 RNase activity...
8:49 AM, Aug 23, 2018  |  BC Innovations | Distillery Therapeutics

Hepatic

INDICATION: Liver disease; drug-induced liver toxicity (DILI) Mouse studies suggest inhibiting TGFBR1 could help treat liver disease and DILI. In mouse models of chemical-induced chronic and acute liver injury, hepatocyte-specific knockout of TGFBR1 or a tool...
8:49 AM, Aug 23, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine/metabolic

INDICATION: Cushing disease Patient sample and cell culture studies suggest the BRAF V600E inhibitor Zelboraf vemurafenib could help treat Cushing disease, which involves excessive cortisol production triggered by ACTH-secreting pituitary adenomas. In 91 tumor samples from...
8:49 AM, Aug 23, 2018  |  BC Innovations | Distillery Therapeutics

Inflammation

INDICATION: Inflammation In vitro and mouse studies identified a RORγT inverse agonist that could help treat delayed-type hypersensitivity (DTH)-associated inflammation. Fragment-based screening, chemical synthesis of phenyl-acetamide-based analogs of the screening hit, and in vitro and cell-based...
8:48 AM, Aug 23, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) In vitro, cell culture and mouse studies identified an inhibitor of the SOD1-DERL1 interaction that could help treat familial ALS caused by SOD1 mutations. Screening of a small molecule library, chemical...
8:47 AM, Aug 23, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Lymphoma; acute lymphoblastic leukemia (ALL); ovarian cancer; solid tumors Cell culture and mouse studies suggest anti-PD-1 single-chain variable fragment (scFv)-secreting CAR T cells could help treat Burkitt lymphoma, ALL and solid tumors. In co-culture with...
8:47 AM, Aug 23, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and cell culture studies identified two thiazolidinedione-based dual inhibitors of tau-aggregation and GSK3B that could help treat AD. Chemical synthesis and in vitro testing in enzymatic activity assays of 35...
8:47 AM, Aug 23, 2018  |  BC Innovations | Distillery Therapeutics

Inflammation

INDICATION: Inflammation Patient sample and cell culture studies suggest nitro-fatty acids could help treat STING-associated vasculopathy with onset in infancy (SAVI), an inflammatory disease caused by gain-of-function STING mutations. In fibroblasts from SAVI patients, nitro-fatty acids...
3:55 PM, Aug 16, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology; pulmonary

INDICATION: Dermatology; pulmonary fibrosis Cell culture and mouse studies suggest inhibiting SHP-2 could help treat dermal and pulmonary fibrosis. In primary human dermal fibroblasts stimulated with the fibrosis mediator transforming growth factor β 1(TGFB1), levels of...
9:15 AM, Aug 16, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture studies suggest inhibiting IKK or its scaffold protein NEMO in combination with inhibition of MC-1 could help treat STK11-deficient lung cancer. In a human STK11-deficient lung cancer cell line, the MC-1...

Pages